3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Colorectal Neoplasms
131
Colonic Neoplasms
72
Rectal Neoplasms
61
Breast Neoplasms
61
Stomach Neoplasms
37
Pancreatic Neoplasms
31
Squamous Cell Carcinoma of Head and Neck
27
Esophageal Neoplasms
24
Head and Neck Neoplasms
23
Neoplasm Metastasis
22
Esophageal Squamous Cell Carcinoma
16
Carcinoma, Hepatocellular
16
Adenocarcinoma Of Esophagus
16
Parkinson Disease 4, Autosomal Dominant Lewy Body
14
Neoplasms
11
Nasopharyngeal Carcinoma
11
Adenocarcinoma
7
Urinary Bladder Neoplasms
5
Keratosis, Actinic
5
Cholangiocarcinoma
5
Anus Neoplasms
5
Intestinal Neoplasms
4
Inflammatory Breast Neoplasms
4
Hepatoblastoma
4
Gastrointestinal Neoplasms
4
Digestive System Neoplasms
4
Biliary Tract Neoplasms
4
Laryngeal Neoplasms
3
Hypopharyngeal Neoplasms
3
HIV Infections
3
Interventions
Gemcitabine
12
Mitomycin
11
Cisplatin
10
Carboplatin
8
pembrolizumab
7
Docetaxel
4
toripalimab
3
avelumab
3
atezolizumab
3
Paclitaxel
3
sacituzumab govitecan
2
disitamab vedotin
2
Taxes
2
Specimen Handling
2
Platinum
2
Magnetic Resonance Spectroscopy
2
Injections
2
1,2-diaminocyclohexaneplatinum II citrate
2
vinflunine
1
valrubicin
1
tislelizumab
1
lenvatinib
1
eribulin
1
epacadostat
1
enfortumab vedotin
1
durvalumab
1
dodecyl maltoside
1
Vitamin B 12
1
Standard of Care
1
Ramucirumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Transitional Cell
×
Fluorouracil
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled